Family History Not Associated With Disease Progression in MGUS

Family History Not Associated With Disease Progression in MGUS
Family History Not Associated With Disease Progression in MGUS

A family history of lymphoproliferative disorders is not a risk factor for progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, a study presented at the European Hematology Association (EHA) 21st Congress.1

Previous research has demonstrated that first-degree relatives of patients with MGUS and multiple myeloma have a 2-fold to 3-fold increased risk of a lymphoproliferative disorder.

Further, a family history of a lymphoproliferative disorder has been shown to significantly improve survival in patients with multiple myeloma; however, the impact of family history of a lymphoproliferative disorder on the risk of progression from MGUS to multiple myeloma is unclear.

For the study, researchers analyzed data from 24,126 patients with MGUS diagnosed between 1958 and 2013 and their first-degree relatives identified using nationwide Swedish Registries and the Swedish Cancer Registry.

A positive family history of a lymphoproliferative disorder was defined as patients with MGUS having at least 1 first-degree relative with multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Waldenström macroglobulinemia, or Hodgkin lymphoma.

Results showed that among the 1666 patients who progressed to multiple myeloma, the risk of progression was similar between patients with sporadic MGUS and those with MGUS and a positive family history of any lymphoproliferative disorder (hazard ratio [HR], 1.17; 95% CI, 0.90-1.53; P =.23).

Similar findings were observed when only patients with a family history of multiple myeloma were included.


1. Aradottir K, Lund SH, Landgren O, Bjorkholm M, Turesson I, Kristinsson SY. Impact of family history on risk of progression of MGUS to multiple myeloma: a population-based study. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs